He believes Civica has uncovered a business model that is “pro-competition,” and one that others throughout the biopharma industry can adopt as well. We’ll tackle specifically how those relationships will come together in part two of this article next month.įirst, VanTrieste explains the market challenges, and the relief his new organization and partnerships will bring to patients. A major role in this supply chain-to-come will be CDMOs. You’ve read that correctly: by the end of 2019.

The initial business plan calls for Civica to bring a “bundle” of 14 generic drugs - all now in shortage or unsteady supply at hospitals - directly from manufacturers to hospitals by the end of this year. Still, what he believes is a solution to end the supply shortages of common generic drugs dogging hospitals and patients for years is a not-for-profit organization - albeit one VanTrieste describes as “a disruptive force to serve patients.” Already, The Mayo Clinic, Intermountain Healthcare, and over two dozen healthcare systems have fueled this potentially potent new force, with investments of up to $10 million each. flow in the opposite direction, early in our discussion of his newly formed organization, Civica Rx (Civica), President & CEO Martin VanTrieste proclaims, “I am a capitalist.” Perhaps because today some political currents in the U.S. By Louis Garguilo, Chief Editor, Outsourced Pharma

Super sume pro license key